Interchangeable Biosimilars May Qualify For ‘Immediate Substitution’ In Medicare Part D
Proposed policy could help promote uptake of interchangeable biosimilars to AbbVie’s blockbuster Humira. However, some PBMs and insurers are not persuaded that interchangeability is a useful distinction so may not rush to take advantage of the new flexibility.
You may also be interested in...
Pfizer has responded to Generics Bulletin’s queries regarding its bid to win an interchangeability designation for its Abrilada (adalimumab-afzb) biosimilar to AbbVie’s Humira reference product.
Just-in-time education may be preferred, so patients and providers see it as they are making decisions, OTBB Director Sarah Yim says in an interview.
Biologics with their brand name dropped from the label could become the alternative to an ‘authorized biosimilar,’ which is not allowed under the law.